Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Charles E Geyer
NRG Oncology
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
673 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cross Cancer Institute
Edmonton, Alberta, Canada
- Bcca-Vancouver Cancer Centre
Vancouver, British Columbia, Canada
- Bcca-Vancouver Island Cancer Centre
Victoria, British Columbia, Canada
- the Moncton Hospital
Moncton, New Brunswick, Canada
- Doctor H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada
- William Osler Health System-Brampton Civic Hospital
Brampton, Ontario, Canada
- London Regional Cancer Program
London, Ontario, Canada
- Algoma District Cancer Program Sault Area Hospital
Sault Ste. Marie, Ontario, Canada
- University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
- Csss Champlain-Charles Le Moyne
Greenfield Park, Quebec, Canada
- Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
- Katmai Oncology Group
Anchorage, Alaska, United States
- Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
- Ctca at Western Regional Medical Center
Goodyear, Arizona, United States
- Banner-University Medical Center Phoenix
Phoenix, Arizona, United States
- Banner Boswell Medical Center
Sun City, Arizona, United States
- Nea Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas, United States
- Kaiser Permanente-Anaheim
Anaheim, California, United States
- Kaiser Permanente-Deer Valley Medical Center
Antioch, California, United States
- Kaiser Permanente-Baldwin Park
Baldwin Park, California, United States
- Kaiser Permanente-Bellflower
Bellflower, California, United States
- Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States
- Uc Irvine Health Cancer Center-Newport
Costa Mesa, California, United States
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Kaiser Permanente Dublin
Dublin, California, United States
- Kaiser Permanente-Fontana
Fontana, California, United States
- Kaiser Permanente-Fremont
Fremont, California, United States
- Palo Alto Medical Foundation-Fremont
Fremont, California, United States
- Washington Hospital
Fremont, California, United States
- Kaiser Permanente-Fresno
Fresno, California, United States
- Kaiser Permanente - Harbor City
Harbor City, California, United States
- Kaiser Permanente-Irvine
Irvine, California, United States
- Loma Linda University Medical Center
Loma Linda, California, United States
- Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
- Kaiser Permanente West Los Angeles
Los Angeles, California, United States
- Kaiser Permanente-Modesto
Modesto, California, United States
- Memorial Medical Center
Modesto, California, United States
- Palo Alto Medical Foundation-Camino Division
Mountain View, California, United States
- Kaiser Permanente-Oakland
Oakland, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Apr 2019
- Primary completion
- 30 Apr 2024
- Completion
- 4 Apr 2025
- Last update posted
- 29 May 2026
- Registered enrollment
- 190
- Registry id
- NCT03199885
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.